The outlook isn't rosy—but could there be light at the end of the tunnel? The biopharma sector finds itself in uncertain territory, navigating a perfect storm of challenges—from looming tariff threats and unexpected regulatory shake-ups to deep R&D cuts and stubbornly high inflation. For industry leaders and investors alike, the stakes have rarely felt higher. While the road ahead may look daunting, understanding the landscape and preparing strategically could uncover hidden